How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of the criteria considered by the committee, and the clinical and economic considerations reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about pirtobrutinib

Marketing authorisation indication

2.1

Pirtobrutinib (Jaypirca, Eli Lilly & Company) is indicated for 'the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor'.

Price

2.3

The list price for pirtobrutinib is £2,081.50 for a 28-pack of 50-mg tablets and £8,326.00 for a 56-pack of 100-mg tablets (excluding VAT; from company submission).

2.4

The company has a commercial arrangement (simple discount patient access scheme). This makes pirtobrutinib available to the NHS with a discount. The size of the discount is commercial in confidence.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Eli Lilly & Company will be included here when guidance is published.